BRPI0920053B8 - composto pirazolilaminopiridina, composição contendo o dito composto e uso do mesmo para tratar câncer - Google Patents

composto pirazolilaminopiridina, composição contendo o dito composto e uso do mesmo para tratar câncer

Info

Publication number
BRPI0920053B8
BRPI0920053B8 BRPI0920053A BRPI0920053A BRPI0920053B8 BR PI0920053 B8 BRPI0920053 B8 BR PI0920053B8 BR PI0920053 A BRPI0920053 A BR PI0920053A BR PI0920053 A BRPI0920053 A BR PI0920053A BR PI0920053 B8 BRPI0920053 B8 BR PI0920053B8
Authority
BR
Brazil
Prior art keywords
compound
pyrazolylaminopyridine
composition containing
treat cancer
present
Prior art date
Application number
BRPI0920053A
Other languages
English (en)
Inventor
Lin Hong
Leroy Adams Jerry
Kasparec Jiri
Mellinger Mark
W Johnson Neil
Xie Ren
H Faitg Thomas
Peng Xin
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920053(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BRPI0920053A2 publication Critical patent/BRPI0920053A2/pt
Publication of BRPI0920053B1 publication Critical patent/BRPI0920053B1/pt
Publication of BRPI0920053B8 publication Critical patent/BRPI0920053B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

pirazolilaminopiridinas como inibidores da fak. a presente invenção está relacionada a um composto de fórmula (i) ou um sal famacêutico aceitável do mesmo, onde r1,r2, r3, r11, r12, r13,q, z e p são conforme descritos na presente invenção. os compostos da presente invenção são úteis para o tratamento dos cânceres.
BRPI0920053A 2008-10-27 2009-10-27 composto pirazolilaminopiridina, composição contendo o dito composto e uso do mesmo para tratar câncer BRPI0920053B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US61/108,568 2008-10-27
US17851709P 2009-05-15 2009-05-15
US61/178,517 2009-05-15
US24243209P 2009-09-15 2009-09-15
US61/242.432 2009-09-15
PCT/US2009/062163 WO2010062578A1 (en) 2008-10-27 2009-10-27 Pyrazolylaminopyridines as inhibitors of fak

Publications (3)

Publication Number Publication Date
BRPI0920053A2 BRPI0920053A2 (pt) 2015-12-15
BRPI0920053B1 BRPI0920053B1 (pt) 2019-11-26
BRPI0920053B8 true BRPI0920053B8 (pt) 2021-05-25

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920053A BRPI0920053B8 (pt) 2008-10-27 2009-10-27 composto pirazolilaminopiridina, composição contendo o dito composto e uso do mesmo para tratar câncer

Country Status (35)

Country Link
US (6) US20100113475A1 (pt)
EP (1) EP2421537B1 (pt)
JP (1) JP5642689B2 (pt)
KR (1) KR101512217B1 (pt)
CN (1) CN102264371B (pt)
AR (1) AR073993A1 (pt)
AU (1) AU2009320144B2 (pt)
BR (1) BRPI0920053B8 (pt)
CA (1) CA2741760C (pt)
CL (1) CL2011000933A1 (pt)
CO (1) CO6361929A2 (pt)
CR (1) CR20110264A (pt)
CY (1) CY1116399T1 (pt)
DK (1) DK2421537T3 (pt)
DO (1) DOP2011000113A (pt)
EA (1) EA021927B1 (pt)
ES (1) ES2539835T3 (pt)
HR (1) HRP20150531T1 (pt)
IL (1) IL212444A (pt)
JO (1) JO3067B1 (pt)
MA (1) MA32727B1 (pt)
MX (1) MX2011004369A (pt)
MY (1) MY161890A (pt)
NZ (1) NZ592477A (pt)
PE (1) PE20110941A1 (pt)
PL (1) PL2421537T3 (pt)
PT (1) PT2421537E (pt)
RS (1) RS54045B1 (pt)
SG (1) SG195608A1 (pt)
SI (1) SI2421537T1 (pt)
SM (1) SMT201500157B (pt)
TW (1) TWI454467B (pt)
UY (1) UY32200A (pt)
WO (1) WO2010062578A1 (pt)
ZA (1) ZA201102892B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
CA2840211A1 (en) * 2011-06-28 2013-01-03 Glaxosmithkline Intellectual Property (No.2) Limited Method of administration and treatment
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
EA201890161A1 (ru) 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
CN108948019B (zh) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
AU2019236402A1 (en) 2018-03-12 2020-10-01 Assistance Publique-Hôpitaux De Paris (Aphp) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
CA3109617A1 (en) 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
CN111377871B (zh) * 2018-12-27 2021-03-19 海创药业股份有限公司 一种fak抑制剂及其联合用药物
JP2022525186A (ja) 2019-03-15 2022-05-11 ザ ジェネラル ホスピタル コーポレイション Ｔｅａｄ転写因子新規小分子阻害剤
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
CN119499253A (zh) * 2024-11-15 2025-02-25 贵州医科大学 一种化合物在抑制Aurora和JAK激酶家族活性及在几种肿瘤治疗方面的应用
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
DE69928411D1 (de) * 1998-09-08 2005-12-22 Agouron Pharma Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
EP2134689B1 (en) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物

Also Published As

Publication number Publication date
KR20110080172A (ko) 2011-07-12
IL212444A0 (en) 2011-06-30
HRP20150531T1 (hr) 2015-06-19
PL2421537T3 (pl) 2015-08-31
PE20110941A1 (es) 2012-02-08
JP2012506876A (ja) 2012-03-22
KR101512217B1 (ko) 2015-04-15
SI2421537T1 (sl) 2015-06-30
BRPI0920053A2 (pt) 2015-12-15
MX2011004369A (es) 2011-05-25
EA201170617A1 (ru) 2011-12-30
EA021927B1 (ru) 2015-09-30
JP5642689B2 (ja) 2014-12-17
JO3067B1 (ar) 2017-03-15
ZA201102892B (en) 2012-02-29
CL2011000933A1 (es) 2011-10-21
HK1161680A1 (en) 2012-08-03
TW201028394A (en) 2010-08-01
US20110269774A1 (en) 2011-11-03
CR20110264A (es) 2011-10-04
US20100113475A1 (en) 2010-05-06
WO2010062578A1 (en) 2010-06-03
US20160095841A1 (en) 2016-04-07
NZ592477A (en) 2013-01-25
US20110207743A1 (en) 2011-08-25
CN102264371B (zh) 2013-10-02
CN102264371A (zh) 2011-11-30
CA2741760C (en) 2016-02-23
EP2421537B1 (en) 2015-04-08
DK2421537T3 (da) 2015-06-22
UY32200A (es) 2010-05-31
BRPI0920053B1 (pt) 2019-11-26
EP2421537A4 (en) 2012-06-13
MA32727B1 (fr) 2011-10-02
AR073993A1 (es) 2010-12-15
EP2421537A1 (en) 2012-02-29
ES2539835T3 (es) 2015-07-06
CY1116399T1 (el) 2017-02-08
US9012479B2 (en) 2015-04-21
DOP2011000113A (es) 2011-07-15
TWI454467B (zh) 2014-10-01
CO6361929A2 (es) 2012-01-20
SMT201500157B (it) 2015-09-07
SG195608A1 (en) 2013-12-30
MY161890A (en) 2017-05-15
AU2009320144B2 (en) 2013-11-21
RS54045B1 (sr) 2015-10-30
CA2741760A1 (en) 2010-06-03
AU2009320144A1 (en) 2010-06-03
IL212444A (en) 2015-11-30
PT2421537E (pt) 2015-07-03
US9446034B2 (en) 2016-09-20
US20150265589A1 (en) 2015-09-24
US20140107131A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
BRPI0915084B8 (pt) composto, e, composição farmacêutica
BRPI0916735B8 (pt) compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201100030A1 (ru) Пиразольные соединения 436
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
EA201300211A1 (ru) N-ацилсульфонамидные промоторы апоптоза
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
UA94129C2 (ru) Соединения для ингибирования митоза
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
EA201170772A1 (ru) Органические соединения
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF